Pharmaceuticals

An advisory committee voted against expectations on a closely watched neurological therapy, and the discussion is spreading well beyond biotech circles.

Enforcement actions against compounded GLP-1 sellers are expanding, with new warning letters and platform-level takedowns being tracked in real time.

Speculation about the next negotiation-eligible drug list is rebuilding, with policy analysts circulating probability-ranked candidate sets.

Patent-cliff exposure at several large-cap pharmas is driving a fresh wave of takeout speculation across mid-cap biotech.

Newly presented real-world outcomes data for approved Alzheimer's therapies is fueling disagreement between clinical and investor communities.

Case reports of adverse events in a gene-therapy program are circulating ahead of any official communication, prompting class-wide caution.

Late-breaking abstract titles for the upcoming oncology meeting are out, and readthrough speculation is driving positioning in presenting companies.

Legislative chatter around subscription-style incentives for novel antibiotics is picking up, with bipartisan sponsor counts growing.

Discussion of tax and procurement incentives for domestic active-pharmaceutical-ingredient manufacturing is circulating among policy and supply-chain accounts.